OSE Immunotherapeutics SA
PAR:OSE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
OSE Immunotherapeutics SA
PAR:OSE
|
FR |
|
Spark New Zealand Ltd
NZX:SPK
|
NZ |
|
Bringspring Science and Technology Co Ltd
SZSE:300290
|
CN |
|
Sino Biopharmaceutical Ltd
HKEX:1177
|
HK |
|
Shenzhen Forms Syntron Information Co Ltd
SZSE:300468
|
CN |
|
C
|
CGS International Inc
OTC:CGSI
|
US |
|
BRD Klee A/S
CSE:KLEE B
|
DK |
|
C
|
Change Healthcare Inc
F:1CB
|
US |
|
BYC Co Ltd
KRX:001460
|
KR |
|
B
|
Bajaj Electricals Ltd
NSE:BAJAJELEC
|
IN |
|
E
|
Eisen und Huettenwerke AG
F:EIS
|
DE |
|
Subsea 7 SA
OTC:ACGYF
|
UK |
OSE Immunotherapeutics SA
OSE Immunotherapeutics SA develops immunotherapy products for cancer and auto-immune disease. The company is headquartered in Nantes, Pays De La Loire and currently employs 61 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.
OSE Immunotherapeutics SA develops immunotherapy products for cancer and auto-immune disease. The company is headquartered in Nantes, Pays De La Loire and currently employs 61 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.
